Get the Stockscreener App
1,019.89
2.89%
30.02
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,019.89, with a volume of 1.94M.
It is up +2.89% in the last 24 hours and up +9.57% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$989.87
Open:
$994.75
24h Volume:
1.94M
Relative Volume:
0.63
Market Cap:
$909.31B
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
36.71
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+3.18%
1M Performance:
+9.57%
6M Performance:
-0.43%
1Y Performance:
+36.51%
1-Day Range:
$992.00
$1,020.00
1-Week Range:
$943.26
$1,018.82
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,019.70 | 882.71B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
229.65 | 539.84B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
207.46 | 367.25B | 62.82B | 3.60B | 19.98B | 2.0274 |
AZN
Astrazeneca Plc
|
186.72 | 286.19B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
149.40 | 282.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Eli Lilly (LLY) Launches Alzheimer's Therapy Lormalzi in India - GuruFocus
Eli Lilly & Co. stock (US5324571083): Strong Q1 earnings beat and raised FY2026 guidance - AD HOC NEWS
Jim Cramer’s Take on 24 Stocks: Cisco, Eli Lilly, and Ford - Insider Monkey
Eli Lilly's Foundayo, Lower-Dose Zepbound Help Sustain Weight LossEli Lilly (NYSE:LLY) - Benzinga
Encouraging Results for Eli Lilly's Orforglipron in Weight Loss Trials - GuruFocus
Lilly CEO David Ricks keeps eye on future while company celebrates history - Indianapolis Business Journal
BMO reiterates Eli Lilly stock Outperform on maintenance data - Investing.com
Parkland School Board tables vote on tax break for Eli Lilly - The Morning Call
Eli Lilly stock (US5324571083): Long-term weight loss trial success boosts obesity drug prospects - AD HOC NEWS
Eli Lilly on big upswing in research as Indy company marks 150 years - AOL.com
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India - NDTV
Zacks Investment Ideas feature highlights Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez - Yahoo Finance Singapore
Eli Lilly launches Alzheimer’s drug in India at $957 per vial - Investing.com Nigeria
Eli Lilly launches Alzheimer’s drug in India at $957 per vial By Investing.com - Investing.com South Africa
Eli Lilly launches Alzheimer's drug Donanemab in India - Reuters
Alzheimer's a key part of Eli Lilly's India specialty medicine push, says company's country head Winselow - The Economic Times
Eli Lilly Clinical Trial Shows Its Obesity Drugs Can Cause Weight Loss And Help Maintain It - Stocktwits
Can Novo Nordisk close the gap to Eli Lilly? - Investors' Chronicle
Lilly, J&J CEOs top pharma’s highest paid list—again - BioSpace
Eli Lilly & Company CEO reflects on business’ 150-year history in Indianapolis - Fox 59
Eli Lilly (LLY) Reports Long-Term Weight Loss Success in Latest Trials - GuruFocus
AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years - WRTV
Lilly reports weight maintenance data for Foundayo, Zepbound - Investing.com
Lilly reports weight maintenance data for Foundayo, Zepbound By Investing.com - Investing.com Australia
Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study finds - Reuters
Gut Bugs and Lilly’s Foundayo Both Help Curb Yo-Yo Diet Effect - Bloomberg.com
Is It Too Late to Buy Eli Lilly and Co (LLY) After 4.4% Rally? G - GuruFocus
Food partnership, life sciences speaker series unveiled at Lilly’s 150th anniversary event - Inside INdiana Business
Stock Market Today (LIVE): Wegovy Data Targets Eli Lilly's Crown; Amazon Launches 30-Minute Delivery - The Motley Fool
Lilly Invests $4.5B to Expand Facilities - Powder & Bulk Solids
Eli Lilly funds cold storage so food banks can serve 5M meals a year - Stock Titan
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries - investor.lilly.com
Eli Lilly Breakthrough Drives Russell 1000 Index Buzz - Kalkine Media
Eli Lilly acquires Centessa Pharmaceuticals in $7.8bn deal - Financier Worldwide
Roche, Eli Lilly Alzheimer’s Blood Test Cleared In EuropeEli Lilly (NYSE:LLY), Roche Holding (OTC:RHHB - Benzinga
Eli Lilly & Co. stock (US5324571083): Shares surge 4.36% on Q1 beat, raised guidance - AD HOC NEWS
Eli Lilly's Oral Obesity Drug Trails Expectations in First Month - thelec.net
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. - AOL.com
NVO Stock Pops Premarket: Novo Nordisk Unveils Fresh Wegovy Data That Could Narrow Eli Lilly’s Obesity Lead - Stocktwits
HIMS Stock Crashes Overnight After Brutal Q1 — But An Investor Says Novo, Lilly Deals Could Make It ‘Netflix Of Healthcare’ - Stocktwits
Eli Lilly pauses obesity awareness campaign in India after drug regulator warning - BusinessLine
Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY) - Insider Monkey
What's Ailing the Biggest Healthcare ETF? Eli Lilly, GLP-1 Troubles Are a Start. -- Barrons.com - Moomoo
Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity - Reuters
Exclusive-Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity - AOL.com
Eli Lilly and Co Stock (LLY) Moved Up by 4.36% on May 11: Drivers Behind the Movement - TradingKey
Eli Lilly CFO Lucas Montrace explains what drove 56% year-over-year revenue beat - qz.com
Why is Eli Lilly stock climbing today? - Investing.com
Why Eli Lilly (LLY) is a Top Momentum Stock for the Long-Term - Yahoo Finance Singapore
Eli Lilly stock (US5324571083): Q1 revenue surge 56% on obesity drug boom - AD HOC NEWS
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):